Uppsala, Sweden

Ulrika Backman



Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ulrika Backman: Innovator in Pharmaceutical Chemistry

Introduction

Ulrika Backman is a prominent inventor based in Uppsala, Sweden. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that have therapeutic applications.

Latest Patents

Ulrika Backman holds two patents, with her latest innovations focusing on quinoline derivatives. These compounds are recognized for their potential use as tyrosine kinase inhibitors. The patents detail a compound of formula Quinoline derivatives and their use as tyrosine kinase inhibitors, as well as pharmaceutically acceptable salts thereof. Additionally, a pharmaceutical composition containing a therapeutically effective amount of the compound is described. The applications of these compounds are extensive, including treatments for cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke, ischemic myocardium, atherosclerosis, macular edema, and psoriasis.

Career Highlights

Ulrika Backman is associated with Clanotech AB, where she continues to advance her research and development efforts. Her work has positioned her as a key figure in the pharmaceutical industry, contributing to innovative solutions for complex health issues.

Collaborations

Ulrika collaborates with notable colleagues, including Jacob Westman and Natalia Nekhotiaeva. These partnerships enhance her research capabilities and foster a collaborative environment for innovation.

Conclusion

Ulrika Backman exemplifies the spirit of innovation in pharmaceutical chemistry through her groundbreaking patents and collaborative efforts. Her work has the potential to significantly impact the treatment of various medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…